title: Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas.
authors.affiliation: Department of Surgery, Rotterdam Cancer Institute (Dr. Daniel den Hoed Kliniek, The Netherlands.
authors.forename: A M
authors.initials: AM
authors.lastname: Eggermont
authors.forename: H
authors.initials: H
authors.lastname: Schraffordt Koops
authors.forename: J M
authors.initials: JM
authors.lastname: Klausner
authors.forename: P M
authors.initials: PM
authors.lastname: Schlag
authors.forename: B B
authors.initials: BB
authors.lastname: Kroon
authors.forename: G
authors.initials: G
authors.lastname: Ben-Ari
authors.forename: F J
authors.initials: FJ
authors.lastname: Lejeune
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005121:Extremities; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014409:Tumor Necrosis Factor-alpha